Articles Tagged With: vaccine
-
COVID-19 Vaccine Receipt Was Associated with Better Clinical Outcomes in U.S. Veterans
An observational study from the Department of Veterans Affairs found that individuals who received the 2024-2025 COVID-19 vaccine and the influenza vaccine on the same day had fewer emergency department visits, COVID-19-associated hospitalizations, and deaths related to COVID-19 compared to a group that only received the influenza vaccine.
-
Modified mRNA Influenza Vaccine Shows Superior Efficacy Over Standard Inactivated Vaccine
In a Phase III randomized controlled trial of adults aged 18 to 64 years, a quadrivalent nucleoside-modified messenger ribonucleic acid (mRNA) (modRNA) influenza vaccine demonstrated 34.5% relative efficacy against laboratory-confirmed influenza-like illness compared with a licensed inactivated influenza vaccine, meeting criteria for both noninferiority and superiority. The modRNA platform showed enhanced immunogenicity against influenza A strains and strong T-cell responses but did not meet noninferiority criteria for immunogenicity against influenza B strains (although clinical efficacy against B strains could not be determined due to low case counts). The modRNA vaccine was associated with increased reactogenicity but demonstrated an acceptable safety profile, supporting the potential of mRNA technology for next-generation influenza vaccines.
-
One vs. Two Doses of HPV Vaccine
A single dose of either of two human papillomavirus vaccines was as effective as administration of two doses.
-
COVID-19 Vaccine Receipt Was Associated with Better Clinical Outcomes in U.S. Veterans
An observational study from the Department of Veterans Affairs found that individuals who received the 2024-2025 COVID-19 vaccine and the influenza vaccine on the same day had fewer emergency department visits, COVID-19-associated hospitalizations, and deaths related to COVID-19 compared to a group that only received the influenza vaccine.
-
An Oral Vaccine Against Salmonella Paratyphi A Shows Promise
In a Phase IIb controlled human infection model study, the oral live attenuated vaccine CVD 1902 demonstrated 73% efficacy against Salmonella Paratyphi A infection, with a favorable safety profile and robust immunogenicity, supporting advancement toward field trials in endemic populations.
-
Recombinant Herpes Zoster Vaccine in a Medicare Population
Receipt of adjuvanted recombinant herpes zoster vaccine was effective in individuals older than 64 years of age and maintained its efficacy in immunocompromised individuals. Added benefit accrued from receipt of the second vaccine dose, even if its administration was delayed.
-
Routine Boosting Against Tetanus and Diphtheria in Adults: A Time to Reconsider
Slifka and colleagues make a strong argument against the routine booster vaccination of adults against tetanus and diphtheria as recommended by the Centers for Disease Control and Prevention.
-
RSV Vaccination in Severely Immunocompromised Individuals
The antibody response to respiratory syncytial virus vaccination is significantly impaired in many severely immunocompromised individuals.
-
Clostridioides difficile Toxin Vaccine Failed to Prevent Primary Infection in Trial
A Phase III randomized clinical trial on adults 50 years of age and older found that a detoxified toxin A/B vaccine failed to reach its primary endpoint of preventing Clostridioides difficile infection. The vaccine was safe and well tolerated.
-
Preterm Birth and the RSV Vaccine During Pregnancy
The follow-up MATISSE study explored the safety of the respiratory syncytial virus prefusion F (RSVpreF) vaccine in pregnant women and demonstrated no significant increase in preterm birth rates compared to the placebo, although it highlighted geographical and socioeconomic disparities in outcomes.